NEW YORK (GenomeWeb News) – Oligonucleotide synthesis company Integrated DNA Technologies announced today that it has purchased VH Bio's oligonucleotide business.

Under the agreement, IDT will serve VH Bio's oligonucleotide customers from IDT's European synthesis facility, which opened in Leuven, Belgium, this past September. As such, IDT plans to provide current VH Bio customers with a broader product range of quality-controlled oligonucleotides that are available for next-day delivery.
Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.